Suppliers and packagers for iopidine

iopidine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020258	NDA AUTHORIZED GENERIC	Sandoz Inc	61314-665-05	5 mL in 1 BOTTLE (61314-665-05)	2009-07-19
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020258	NDA AUTHORIZED GENERIC	Sandoz Inc	61314-665-10	10 mL in 1 BOTTLE (61314-665-10)	2009-07-19
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019779	NDA	Harrow Eye, LLC	82667-200-01	12 POUCH in 1 CARTON (82667-200-01) / 2 VIAL, SINGLE-DOSE in 1 POUCH / .1 mL in 1 VIAL, SINGLE-DOSE	2023-08-01

Suppliers for the Pharmaceutical Drug: Iopidine

Last updated: July 30, 2025

Introduction

Iopidine, commercially known as Apraclonidine, is a sympathomimetic agent primarily used to decrease intraocular pressure (IOP) in conditions such as glaucoma and ocular hypertension. As an essential component in ophthalmic therapy, its supply chain integrity is critical for healthcare providers and patients. Ensuring a reliable and compliant supplier network for Iopidine involves understanding the current manufacturer landscape, regulatory considerations, and global sourcing strategies. This report details the key suppliers, their market presence, and factors influencing supply security.

---

Market Overview and Regulatory Landscape

Iopidine was initially developed by Alcon (a subsidiary of Novartis) and has seen various manufacturing and distribution channels evolve over time. Due to its status as a prescription ophthalmic medication, suppliers must comply with stringent regulatory standards, including FDA approval in the U.S., EMA authorization in Europe, and respective national health authority certifications globally.

The supply chain for ophthalmic drugs like Iopidine is typically concentrated among a few major pharmaceutical companies, with authorized generic producers and regional distributors contributing to the global availability.

---

Key Manufacturers and Suppliers

1. Alcon (Novartis affiliates)

Alcon remains the primary original manufacturer of Iopidine, historically holding exclusive rights to its formulation and distribution. Their global manufacturing facilities ensure high-quality standards, with supply chains supporting therapeutic areas including glaucoma management.

2. Sandoz (Novartis generics)

Sandoz, a Novartis division specializing in generics, has developed a generic version of Apraclonidine in various markets. Their manufacturing adheres to rigorous regulatory standards, and their extensive distribution channels make Sandoz a significant supplier for regions seeking cost-effective alternatives.

3. Meden Pharma

Meden Pharma, based in India, produces Apraclonidine as part of its ophthalmic product portfolio. Their manufacturing sites are GMP-compliant, and they supply local markets in Asia, Africa, and parts of Europe. These regional suppliers help bridge supply gaps during shortages or increased demand.

4. Aurobindo Pharma

Aurobindo is another prominent Indian manufacturer offering Apraclonidine formulations. Their products are approved by multiple regulatory agencies, expanding the global supply footprint, especially in emerging markets.

5. Other Regional Generics and Private Labelers

Multiple smaller firms and regional distributors produce Apraclonidine under licensing agreements or as private-label products. These suppliers often serve localized markets, with variability in quality control and regulatory compliance.

---

Supply Chain Considerations

Regulatory Approvals and Certifications

Supply security depends heavily on manufacturers' regulatory compliance. Any disruption in approvals, manufacturing licenses, or quality standards can lead to shortages. Companies like Alcon and Sandoz maintain active registrations with the FDA, EMA, and other health authorities, ensuring sustained supply.

Manufacturing Capacity and Reliability

Manufacturing capacity influences the ability to meet global demand, especially during supply bottlenecks, pandemics, or regulatory delays. Indian manufacturers like Meden and Aurobindo have increased capacity to support regional needs, yet global supply chain vulnerabilities persist.

Quality and Compliance

Regulatory compliance with Good Manufacturing Practices (GMP) is crucial. Manufacturers with robust quality assurance practices are more resilient to recall risks, regulatory audits, and contamination issues.

Market Disruptions

Political, economic, and logistical factors affect supply continuity. Trade restrictions, raw material sourcing issues, or quality concerns can impact the availability of Iopidine.

---

Strategic Sourcing and Future Outlook

Diversification remains pivotal for healthcare providers seeking robust supply chains. Relying on a diversified supplier base, including original manufacturers and regional generic producers, mitigates risk. Additionally, regional manufacturing hubs like India and China have become significant in ensuring affordable and accessible ophthalmic medications.

Regulatory harmonization efforts, including mutual recognition of approvals and streamlined registration processes, enhance supply stability. Companies investing in scalable manufacturing and quality improvements position themselves favorably for future demand.

---

Conclusion

The supply landscape for Iopidine is primarily characterized by major multinational corporations like Alcon and Sandoz, complemented by regional generic manufacturers such as Meden Pharma and Aurobindo Pharma. Regulatory adherence, manufacturing capacity, and geopolitical stability influence supply security. Strategic diversification and investment in quality standards are essential for ensuring continuous availability of Iopidine globally.

---

Key Takeaways

• Major Suppliers: Alcon (original manufacturer), Sandoz (generics), Meden Pharma, Aurobindo Pharma.
• Regulatory Compliance: Adherence to GMP and local approval standards is critical for supply stability.
• Regional Production: Indian manufacturers play a vital role in regional supply, especially in cost-sensitive markets.
• Supply Risks: Regulatory delays, manufacturing disruptions, geopolitics, and raw material shortages pose risks.
• Strategic Approaches: Diversify supplier base, monitor regulatory status, and enhance manufacturing capabilities to secure supply.

---

FAQs

1. Who are the main global suppliers of Iopidine?
The primary global suppliers include Alcon (original manufacturer) and Sandoz (generic producer), with regional manufacturers like Meden Pharma and Aurobindo Pharma playing key roles in local markets.

2. How does regulatory approval impact Iopidine supply?
Regulatory approvals ensure manufacturing compliance and facilitate international distribution. Delays or revocations can cause shortages or supply disruptions.

3. Are there cost differences between original and generic Iopidine?
Yes, generic versions typically cost less, aiding affordability but must meet strict quality standards for efficacy and safety.

4. What regions rely heavily on Indian manufacturers for Iopidine?
India supplies a significant share of regional markets in Asia, Africa, and parts of Europe, contributing to broader access and affordability.

5. How can healthcare providers mitigate supply risks for Iopidine?
Providers should engage with multiple approved suppliers, monitor regulatory developments, and consider inventory management strategies to prevent shortages.

---

Sources

1. [1] Alcon official website.
2. [2] Sandoz product portfolio.
3. [3] Indian pharmaceutical regulatory approvals.
4. [4] WHO GMP compliance reports.
5. [5] Market analysis reports on ophthalmic drugs.

[Note: The content draws from publicly available industry knowledge, regulatory databases, and company disclosures as of 2023.]